Foresite Capital Management IV as of June 30, 2021
Portfolio Holdings for Foresite Capital Management IV
Foresite Capital Management IV holds 13 positions in its portfolio as reported in the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Kinnate Biopharma | 30.4 | $225M | 9.7M | 23.28 | |
| Lyell Immunopharma (LYEL) | 29.2 | $216M | 13M | 16.24 | |
| Pharvaris N V (PHVS) | 8.2 | $61M | 3.3M | 18.63 | |
| Aclaris Therapeutics (ACRS) | 8.1 | $60M | 3.4M | 17.56 | |
| Quantum-Si Incorporated Com Cl A (QSI) | 7.4 | $55M | 4.5M | 12.26 | |
| Kura Oncology (KURA) | 5.2 | $39M | 1.8M | 20.85 | |
| Nurix Therapeutics (NRIX) | 4.3 | $32M | 1.2M | 26.53 | |
| Relay Therapeutics (RLAY) | 2.8 | $20M | 556k | 36.59 | |
| Cytokinetics (CYTK) | 1.5 | $11M | 545k | 19.79 | |
| Olema Pharmaceuticals (OLMA) | 1.3 | $9.6M | 342k | 27.98 | |
| Cymabay Therapeutics | 1.1 | $7.8M | 1.8M | 4.36 | |
| Decibel Therapeutics | 0.3 | $2.6M | 298k | 8.60 | |
| Tempest Therapeutics (TPST) | 0.3 | $2.1M | 190k | 11.18 |
